IPG

What IPG does

IPG (Institut de Pathologie et Génétique) is a Belgian non-profit (asbl) integrated diagnostic center founded in 1958 and headquartered at the Biopark in Gosselies, Wallonia. It operates as one of only eight INAMI-approved human genetics centers in Belgium and one of eight approved hereditary metabolic disease centers, consolidating three diagnostic domains — anatomopathology, human genetics, and molecular and cellular biology — under a single roof. With approximately 350 collaborators, IPG performs more than 450,000 analyses per year, serving referring physicians, hospitals, patients, public health authorities, and pharmaceutical/biotech clients. The diagnostic platform combines conventional pathology workflows with advanced genomic technologies including a NovaSeq X Plus NGS sequencer, Oxford Nanopore third-generation sequencing, Optical Genome Mapping (Bionano), an automated immunohistochemistry platform of nine instruments, and the Genius Digital Diagnostics System for AI-assisted digital cytology scheduled for full deployment on 27 April 2026.

IPG's revenue model is anchored in INAMI (National Institute for Health and Disability Insurance) standardized fee schedules, with third-party payment (tiers payant) routed through Belgian mutual health insurers. Diagnostic services are delivered almost exclusively through a physician-referral channel: GPs, gynecologists, and specialists prescribe tests, samples are transported to the Gosselies laboratory via a dedicated courier network, and results are returned through the prescribing physician or via the Walloon Health Network (RSW) and Brussels Health Network. A separate commercial arm, Seqalis (a wholly-owned CRO subsidiary), provides contract research, testing, and R&D services to pharmaceutical, biotech, and academic clients using the institute's certified platforms (qTCR-seq, OGM Bionano, NGS). The organization also operates a BELAC ISO 9001:2015-certified Biobanque (notification BB190020) integrated with the Belgian Virtual Tumour Bank, and runs the founder register of the Eurocat congenital anomalies surveillance network (41 registers across 20 European countries). GTM motion is sales-led and relationship-driven through hospital partnerships (GHdC, CHRSM, CHU Helora, CHU Tivoli, CHU UCL Namur, Epicura, Humani), continuing medical education events ("Les Mardis de la Génétique," "Soirée médecine fœtale"), and structured prescriber outreach tied to nomenclature reforms such as the January 2025 shift to HPV primary screening.

The organization is governed as a non-profit under Belgian law, with a Scientific Council, Board of Directors, Management Committee, and Ethics Committee. General Director Jean-François Ghidetti (since 2018) and Medical Director Dr. Jérémie Gras lead an institution that has progressively professionalized since launching its "Move Up!" strategic plan in 2022 and its "IPG Durable 2025–2027" sustainability agenda. The 2025–2027 product and operational roadmap centers on full digital cytology transformation, continued liquid biopsy development (initiated 2016), and CRO expansion via Seqalis.

Name

IPG

Legal name

Institut de Pathologie et Génétique

Website

https://ipg.be

Company type

Private

Founded year

1958

Operating status

Operating

Headcount range

101–250 employees

Short description

IPG is a Belgian non-profit integrated diagnostic center specializing in anatomopathology, human genetics, and molecular biology. It performs over 450,000 analyses annually for referring physicians, hospitals, and patients, with INAMI-accredited services and a CRO subsidiary.

Ownership category

akta.pro rank

Headquarters

HQ city

Gosselies

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic testing services (anatomopathology, genetics, molecular biology): IPG generates revenue through diagnostic testing services billed to patients and health insurance mutuelles. The institute operates under INAMI fee schedules and applies a third-party payment (tiers payant) system where the portion eligible for reimbursement is billed directly to mutual insurance companies, with the patient responsible for co-payments. Revenue is volume-based on the number of analyses performed (over 450,000 per year).
2. Seqalis CRO services (contract research): Seqalis, a subsidiary of IPG, operates as a Contract Research Organization (CRO) providing tests, consulting, and R&D services to pharmaceutical, biotechnological, and academic sectors. This represents a separate commercial revenue stream from contract research and testing services.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

IPG is an INAMI-recognized integrated diagnostic center delivering anatomopathology, human genetics, and molecular & cellular biology analyses to referring physicians, hospitals, and patients across Belgium. The institute performs more than 450,000 analyses per year, offering specialized testing including NIPT, liquid biopsies, cytogenomic analyses, and operates an ISO-certified Biobank for biomedical research. Through its Seqalis CRO subsidiary, IPG also provides contract research and R&D services to pharmaceutical, biotechnology, and academic clients.

Product overview

IPG (Institut de Pathologie et Génétique) is an integrated diagnostic center offering three core services: Anatomopathology, Human Genetics, and Molecular and Cellular Biology. The institution performs over 450,000 analyses annually with 350 collaborators. Key offerings include the NIPT prenatal test (INAMI reimbursed since 2017), liquid biopsy services, an ISO 9001:2015 certified Biobank, and the AI-assisted Genius Digital Diagnostics System for digital cytology. Through its Seqalis subsidiary, IPG provides CRO services to pharmaceutical and biotech sectors. The institution also contributes to public health through the EUROCAT congenital anomalies registry.

Differentiator

Problem solved

Functional benefit

Brands

• Seqalis: CRO subsidiary providing tests, consulting and R&D to pharmaceutical, biotech and academic sectors in pathology, cytogenomics and molecular biology
• Move Up!
• IPG Durable 2025-2027
• WORDS
• Eurocat Hainaut-Namur

Products and services

• Anatomopathology Services Diagnostic specialty establishing precise diagnoses from various sample types including smears, cytological punctures, endoscopic biopsies, and surgical specimens, covering all organs and systems with pathologies including infections, inflammations, and benign or malignant tumors.
• Human Genetics Center Services Recognized as one of eight human genetics centers in Belgium, offering multidisciplinary care for patients with genetic diseases or hereditary risks through medical genetics, oncogenetics, prenatal and preconception consultations.
• Molecular and Cellular Biology Services Diagnostic department covering constitutional genetics, oncological genetics, and molecular microbiology using technologies including PCR, DNA sequencing, NGS Illumina, and long-read sequencing.
• NIPT (Non-Invasive Prenatal Testing)

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature10 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Seqalis (CRO subsidiary)coreOthersSeqalis is a wholly-owned subsidiary of IPG that extends IPG's expertise in Pathology, Cytogenomics, and Molecular Biology to the contract research organization market. As a CRO, Seqalis provides tests, consulting, and R&D to pharmaceutical, biotechnological, and academic sectors. It uses innovative platforms (qTCR-seq, OGM Bionano, NGS) and is ISO certified, contributing to personalized medicine development.
• Eurocat network (41 registers in 20 countries)coreStrategic or Co-development PartnerEurocat Hainaut-Namur is the founder register of the European Surveillance of Congenital Anomalies network, integrated into IPG since 1995. It collaborates with 41 active registers across 20 European countries, coordinated by the JRC of the European Commission. Activities include surveillance of fetal and neonatal malformations, prenatal analysis, and epidemiological research.
• AVIQ (Agence pour une Vie de Qualité)coreStrategic or Co-development PartnerSince 2023, AVIQ (Agency for Quality of Life, Wallonia) provides quinquennial plan funding for Eurocat Hainaut-Namur's activities in prevention and health promotion, including congenital malformation surveillance, prenatal testing access, and genetic counseling programs across the Walloon region.
• GHdC (Grand Hôpital de Charleroi)coreStrategic or Co-development PartnerGHdC is a major partner hospital collaborating with IPG on the Biobanque (tumorothèque), the WORDS (Wallonian Organisation for Rare DiseaseS) rare disease center (co-directed by Pr. Karin Dahan of IPG and Dr. Jean-François Cambier of GHdC), and the Translational Oncology Laboratory. GHdC provides the majority of oncological samples to the Biobanque.
• Humani (Hôpital Civil Marie Curie)minorStrategic or Co-development PartnerHumani hospital contributes oncological samples to the IPG Biobanque (tumorothèque) and participates in the Eurocat Hainaut-Namur registry surveillance activities.
• Hainaut-Namur hospital network (CHRSM, CHU Helora, CHU Tivoli, CNdG, Epicura, CHU UCL Namur)coreStrategic or Co-development PartnerA network of hospitals in the Hainaut-Namur region (CHRSM Auvelais, CHU Helora Jolimont/Lobbes, CHU Tivoli, CNdG Gosselies, Epicura Hornu, CHU UCL Namur Dinant/Sainte-Elisabeth) collaborates with IPG through the Eurocat Hainaut-Namur registry for surveillance of congenital malformations, data sharing, and referral of complex diagnostic cases.
• Belgian Virtual Tumour Bank (BVT) / Belgian Cancer Registry (BCR)minorStrategic or Co-development PartnerIPG's Biobanque participates in the Belgian Virtual Tumour Bank (BVT), coordinated by the Belgian Cancer Registry (BCR), which facilitates researcher access to tumor samples across Belgian biobanks via a virtual platform (www.virtualtumourbank.be).
• European Reference Networks (ERDERA, EuroBloodNet, EURO-MND, LUNG)coreStrategic or Co-development PartnerIPG's WORDS Rare Disease Centre is a member of multiple European Reference Networks: ERDERA (rare diseases), EuroBloodNet (rare hematological diseases), EURO-MND (rare neurological diseases), and LUNG (rare lung diseases), recognized by the Belgian Ministry of Health as part of the CRMR (Centres de Référence Maladies Rares) network.
• Metabern (European Reference Network for Rare Metabolic Diseases)coreStrategic or Co-development PartnerIPG's metabolic disease team participates in Metabern, the European Reference Network for rare metabolic diseases, providing access to international expertise, latest scientific advances, and enabling contribution to national and international research studies on rare metabolic conditions.
• Metabolics.beminorStrategic or Co-development PartnerIPG's team participates in Metabics.be, the Belgian learned society for metabolic diseases that brings together physicians, researchers, and paramedical specialists in metabolic disorders. An annual national symposium is organized in Belgium for sharing scientific and medical advances.
• Dr. François BeauthierminorImplementation/ SI/ Consulting PartnerIPG has a collaboration agreement with Dr. François Beauthier, who performs all autopsies for IPG under a formal convention. His medical practice handles appointment scheduling for medico-scientific autopsies on behalf of IPG.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Synlab: Europe's largest medical diagnostics network with clinical laboratories across pathology, genetics, and molecular biology. Operates the same integrated multi-specialty lab model as IPG but at pan-European scale, serving both clinical and CRO/pharma customers.
• Cerba Healthcare: International network of specialty clinical laboratories and CRO services focused on advanced diagnostics including genetics, anatomic pathology, and molecular biology. Comparable to IPG in offering integrated specialty testing plus clinical trial support to pharma.
• Unilabs: European clinical diagnostics operator offering pathology, genetics, and specialty testing with a multi-country footprint. Directly comparable to IPG's multi-domain diagnostic model and serves as a benchmark for European scale lab economics.
• Eurofins Genomics: Global genomics and clinical diagnostics CRO serving pharma, biotech, and academic customers with sequencing and molecular biology services. Comparable to IPG via Seqalis in serving pharma/biotech R&D demand with certified molecular biology platforms.
• Sonic Healthcare: Global medical diagnostics operator with pathology, genetics, and specialty testing operations across Europe and Australia. Direct strategic comparable for IPG's integrated diagnostics plus specialty lab franchise economics.

Direct peers

• LHUB-ULB (Laboratoire Hospitalier Universitaire de Bruxelles): Brussels-based integrated university hospital laboratory offering anatomopathology, genetics, and molecular biology diagnostics for Belgian clinicians. Operates the same Belgian specialty lab model as IPG and competes with it for both Brussels and Wallonia referrals.
• AML (Algemeen Medisch Laboratorium / Centrum Medische Genetica UZA): Antwerp-based clinical laboratory and human genetics center within the University Hospital of Antwerp. Comparable to IPG as one of Belgium's eight INAMI-approved human genetics centers and a recognized Belgian diagnostics provider.
• CHU de Liège – Centre de Génétique Humaine: Belgian university hospital human genetics center, one of the eight INAMI-approved genetic centers in Belgium. Direct comparable to IPG in serving Belgian genetics referrals, with overlap on the patient pool and competing for the same national contracts.

Emerging players

• Centogene: Specialty genetics and rare disease diagnostics company operating globally with NIPT, NGS, and biobank services. Directly comparable to IPG's genomics-led diagnostic franchise, particularly for inherited disease testing and pharma partnerships.

Others

• Bio.be / Belgian Society for Medical Genetics: Belgian professional society and ecosystem participant relevant to IPG's human genetics franchise. Adjacent ecosystem participant rather than a competitor, but central to the national rare-disease and clinical genetics policy environment IPG operates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/institut-de-pathologie-et-de-g-n-tique
• Xx.com/ipg_gosselies
• Facebookfacebook.com/profile.php

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IPG